Mercury 2 targets structured tasks with schema-aligned JSON output; supports OpenAI API drop-in integration, for simpler deployment.
Opinion
Visa, Mastercard and Google are building agentic payments. None are solving the real problem.
Visa, Mastercard and Google are all building agentic payments. None of them are solving the real problem. Every major player in payments made the same move in the same quarter.
Microsoft Math Solver is a free tool that uses AI to recognize both printed and handwritten math. It’s particularly strong with geometric proofs and interactive graphing, and it pulls learning ...
When your AI assistant calculates revenue, bonuses, VAT or financial summaries, it isn’t doing math. It’s telling a convincing story about numbers.
Android Central on MSN
Google just doubled its AI reasoning power with the surprise launch of Gemini 3.1 Pro
Gemini 3.1 Pro boosts reasoning and agent-style AI, aiming to solve complex tasks, cut prompt babysitting, and turn Gemini ...
Gemini 3.1 Pro launches with advanced reasoning, scoring 77.1% on ARC-AGI-2, offering enhanced multimodal capabilities.
Google introduces Gemini 3.1 Pro, a major upgrade with dramatically improved reasoning and problem-solving abilities, designed to deliver deeper insights across apps, workflows, and developer tools.
9hon MSN
AI models still suck at math
Just less than before, according to the ORCA test exclusive Current-day LLMs are prediction engines and, as such, they can ...
What if you could hand off your most complex coding challenges, research tasks, or creative projects to an AI that not only understands the full scope of your needs but executes them with precision ...
Newspoint on MSN
Google: Google launches Gemini 3.1 Pro, an advanced AI model that can solve problems in a jiffy.
Google has launched the latest Gemini 3.1 Pro model of its AI assistant. With this update, Google's flagship AI model has ...
National Development Minister Chee Hong Tat is the chair of Singapore’s brand new Growth Capital Workgroup. He was also the chair of the Equities Market Review Group.
Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results